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Abstract: Coronavirus disease 2019 (COVID-19) has been reported to cause cardiovascular compli-
cations such as myocardial injury, thromboembolic events, arrhythmia, and heart failure. Multiple
mechanisms—some overlapping, notably the role of inflammation and IL-6—potentially underlie
these complications. The reported cardiac injury may be a result of direct viral invasion of cardiomy-
ocytes with consequent unopposed effects of angiotensin II, increased metabolic demand, immune
activation, or microvascular dysfunction. Thromboembolic events have been widely reported in both
the venous and arterial systems that have attracted intense interest in the underlying mechanisms.
These could potentially be due to endothelial dysfunction secondary to direct viral invasion or
inflammation. Additionally, thromboembolic events may also be a consequence of an attempt by the
immune system to contain the infection through immunothrombosis and neutrophil extracellular
traps. Cardiac arrhythmias have also been reported with a wide range of implicated contributory
factors, ranging from direct viral myocardial injury, as well as other factors, including at-risk individ-
uals with underlying inherited arrhythmia syndromes. Heart failure may also occur as a progression
from cardiac injury, precipitation secondary to the initiation or withdrawal of certain drugs, or
the accumulation of des-Arg9-bradykinin (DABK) with excessive induction of pro-inflammatory
G protein coupled receptor B1 (BK1). The presenting cardiovascular symptoms include chest pain,
dyspnoea, and palpitations. There is currently intense interest in vaccine-induced thrombosis and
in the treatment of Long COVID since many patients who have survived COVID-19 describe per-
sisting health problems. This review will summarise the proposed physiological mechanisms of
COVID-19-associated cardiovascular complications.
Keywords: COVID-19; SARS-CoV-2; Long COVID; cardiovascular system
1. Introduction
Coronavirus disease (COVID-19), previously known as 2019 novel coronavirus, is
caused by an infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2). It was first detected in December 2019 among a cluster of patients presenting with
pneumonia of unknown cause in Wuhan, Hubei Province, China [1]. On 11 March 2020, it
was declared a pandemic by the World Health Organisation (WHO), and as of 27 December
2020, more than 79 million cases have been reported worldwide with more than 1.7 million
deaths [2,3].
Like SARS-CoV and MERS-CoV, SARS-CoV-2 is from the genus Betacoronavirus from
within the subfamily of Coronavirinae, which arises from the family of Coronoaviridae [1].
It is an enveloped and non-segmented, positive-sense RNA virus with a length of about
29.9kb [4] with huge genomic diversity [5].
A variety of outcomes have been observed amongst patients. In an analysis of 44,672
COVID-19-positive patients in China, 81% were mild (no or mild pneumonia), 4.7% were
critical (respiratory failure, septic shock, and/or multiple organ dysfunction/failure), and
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mortality rate was 2.3% [6]. Patients requiring ICU care were also significantly older
(median age, 66 years vs. 51 years) than those who did not [7]. SARS-CoV-2 infection has
been associated with cardiovascular complications (Figure 1), namely myocardial injury
and myocarditis (36% of 2736 patients), thromboembolic events (25% of 81 patients), heart
failure and cardiomyopathy (23% of 191 patients), arrhythmias (16.7% of 138 patients),
and acute coronary syndromes (0.96% of 4702 patients) [7–12]. Furthermore, COVID-19
symptoms and complications may persist for months after the initial infection in what has
been termed as Long COVID.
Figure 1. Summary of the cardiovascular complications associated with COVID-19.
2. Epidemiology of Cardiovascular Complications
Thromboembolic events such as deep vein thrombosis (DVT), pulmonary embolism
(PE), and arterial thrombosis have been observed frequently during the infection [13,14].
Among patients in the intensive care unit (ICU), as many as 25% developed venous throm-
boembolisms, and the incidence of PEs were found to be more common in COVID-19 acute
respiratory distress syndrome (ARDS) as compared to ARDS of other causes [9,15,16]. Fur-
thermore, an autopsy sample of 12 patients who had died of COVID-19 had an incidental
finding of DVT, and a third were discovered to have had a PE as the cause of death [17]. The
pooled mortality of arterial and venous thromboembolisms, based on a systemic review
and meta-analysis of 8271 patients across UK, USA, Europe, and China, was estimated to
be at 23% [18].
Myocardial injury was another complication commonly reported in patients with
acute COVID-19 infection. It is defined as an evidence of elevated cardiac troponin levels
with at least one value above the 99th percentile upper reference limit in the absence of
myocardial ischaemia [19]. Presenting features include chest pain, dyspnoea, dysrhythmia,
and acute left ventricular dysfunction. A study of 2736 SARS-CoV-2 patients in the U.S.
found that up to 36% have elevated troponin levels early in the course of the disease [10,20].
Those with pre-existing coronary artery disease, cerebrovascular disease, and chronic
HF were more likely to develop myocardial injury [10,21]. Elevated troponins during
hospitalisation were also associated with an increased risk of requiring ventilation, fatal
ventricular arrhythmias, and a 59.6% mortality risk [21,22].
While uncommon, there have been reports from the U.S. and Italy of acute coronary
syndromes (ACS) occurring as the initial presentation or during hospitalisation for COVID-
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19 [23,24]. Among these cases, approximately one-third were found to have non-obstructive
coronary artery disease [23,24]. A multicentre study consisting of 4702 patients across
17 sites in Italy, Spain, and Switzerland observed ACS to occur in 0.96% of COVID-19
patients, with an in-hospital mortality rate of 27.3%. This observed mortality rate was
thrice that of SARS-CoV-2-negative patients presenting with ACS [11].
Arrhythmia was a common complication observed in 16.7% of 138 SARS-CoV-2-
positive patients in a hospital in China [7]. It was observed to occur more frequently in
patients requiring ICU admission than those who did not [25]. The development of acute
malignant arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or atrioven-
tricular block in patients hospitalised for COVID-19, was associated with a significantly
increased mortality [26]. In a systematic review and meta-analysis of 17435 patients across
11 countries, mortality was found to be 20.3% amongst hospitalised COVID-19 patients
who developed arrhythmia [27]. Higher levels of troponin have been correlated with an
increased incidence of malignant ventricular arrhythmia, suggesting that arrhythmia may
be the consequence of other complications [22,25,26].
Heart failure (HF) was observed in 23% of 191 SARS-Cov-2-positive inpatients in
China [12]. A retrospective study of 113 deceased patients observed that nearly half had HF
as a complication [28]. Furthermore, those with underlying cardiovascular co-morbidities,
such as chronic hypertension, were more likely to develop HF [28]. HF patients were found
to be at a higher risk of thromboembolic events, ARDS, severe hypotension, and death [29].
The mortality rate of 77 SARS-CoV-2-positive patients in a hospital in Spain who developed
acute HF was observed to be as high as 46.8% [30].
Signs and symptoms of cardiovascular complications, such as dyspnoea and chest
pain, may have significant overlap with COVID-19. In addition, cardiovascular com-
plications have been observed to occur frequently during the course of the disease. As
such, cardiovascular complications should always be considered especially in more severe
COVID-19 cases, such as those requiring hospitalisation. A group of patients that may have
to be monitored more carefully are those with underlying cardiovascular co-morbidities. It
was observed that these patients were more likely to require hospitalisation, admission to
ICU, and had poorer mortality outcomes [6,7,31–33].
The diverse and frequent cardiovascular complications observed in a respiratory
infection such as COVID-19, as well as the preponderance for those with cardiovascular co-
morbidities, suggests the complex nature of this disease. We will now review the potential
pathophysiological mechanisms that underlie these cardiovascular complications.
3. Pathophysiology of COVID-19-Associated Cardiovascular Complications
Multiple factors possibly contribute to the cardiovascular complications observed in
association with COVID-19 infections. These may include systemic inflammation, direct
invasion of cardiovascular tissue, and medications and so forth. (Figure 2) The following
sections will review the potential mechanisms as to how cardiovascular complications may
arise at various stages of the disease.
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Figure 2. Summary of the possible pathophysiological mechanisms underlying COVID-19-associated cardiovascular
complications. p38 Mitogen-Activated Protein Kinase (p38 MAPK); Angiotensin II (Ang II); T-Helper-1 (Th1); Nicotinamide
Adenine Dinucleotide Phosphate Oxidase 2 (Nox2); Neutrophil Extracellular Traps (NETs); von Willebrand (vWF) factor;
Toll-Like Receptor (TLR); Tissue-Factor (TF); Damage-Associated Molecular Patterns (DAMPs); Factor VIII (VIII); Human
Ether-a-go-go-Related Gene (hERG); Interleukin (IL); Tumour Necrosis Factor (TNF); Des-Arg9-Bradykinin (DABK); G-
protein coupled receptor B1 (BK1).
3.1. SARS-CoV-2 Entry into Cells
Viruses such as SARS-CoV-1 and SARS-CoV-2 have been known to interact with
ACE2 [34,35]. Complications can arise as a direct consequence of the virus’ entry into tissue
that express ACE2. ACE2 is a widely expressed, membrane-associated aminopeptidase
found in the heart, lungs, pericytes, and vessels, among others [1,25,36]. The transmem-
brane spike glycoprotein that protrudes from SARS-CoV-2’s surface allows interaction
with ACE2 and facilitates the virus’s entry into the cell [37]. Entry into myocardial tissue
could disable or destroy the host cell, contributing to the release of danger signals and
activation of the host’s immune response, resulting in myocardial injury and myocardi-
tis [20,25,38]. Entry of the virus into pericytes may potentially cause local microvascular
inflammation, leading to severe microvascular dysfunction and, consequently, myocardial
infarction [1]. The combination of the damage caused to myocardial or conducting tissue
and a SARS-CoV-2-induced ACS may contribute to arrhythmia [25]. Moreover, HF patients
express high levels of ACE2, potentially increasing the risk of a direct viral infection of
the myocytes and further exacerbation [39]. Direct invasion of the vascular endothelium
via ACE2 receptors may contribute to disordered cytokine signalling alongside the release
of damage-associated molecular patterns (DAMPs), which may contribute to thrombi
formation [40]. Viral entry via ACE2 receptors present on the pulmonary endothelial
surface may result in the formation of pulmonary microthrombi as a means to limit viral
invasion through a process known as immunothrombosis [41]. While the cardiovascular
complications may be a result of the site of viral invasion, ACE2 also interacts with other
molecular pathways that can potentially affect the cardiovascular system.
Similar to SARS-CoV-1, the binding of SARS-CoV-2 to ACE2 has been hypothesised
to downregulate the receptor’s function of degrading angiotensin II [34]. Excessive an-
giotensin II potentially activates the pro-thrombotic p38 Mitogen-Activated Protein Kinase
(MAPK) pathway, which may lead to thromboembolic events [35]. Angiotensin II may also
induce Nox2-related reactive oxygen species (ROS) production, resulting in myocardial
injury [42]. Downregulation of ACE2 may cause des-Arg9-bradykinin (DABK) accumula-
tion and excessive G-protein-coupled receptor B1 (BK1) activation, potentially contributing
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to HF [43]. Beyond the local inflammatory effects caused by the virus’s entry, a systemic
inflammatory response has been proposed to play an essential role in cardiovascular
complications.
3.2. The Role of Systemic Inflammation
It is hypothesised that SARS-CoV-2 may induce an excessive acute systemic inflamma-
tory response causing endothelial dysfunction and the activation of complement pathways,
platelets, von Willebrand factor, Toll-like receptors, and tissue factor pathway. This may
result in venous and arterial thrombosis [15,44–46]. Endothelial dysfunction, together
with pathogenic complement activation, may result in diffuse thrombotic microangiopathy,
further contributing to thrombosis [14]. The infection has also been observed to induce a
disproportionate increase in factor VIII, high concentrations of circulating microvesicles,
and neutrophil extracellular traps (NETs), all components that may increase coagulabil-
ity [15,47]. Furthermore, NETs which are pro-inflammatory and pro-thrombotic have been
found to be elevated in SARS-CoV-2-positive patients, which could be an explanation for the
thrombosis observed in COVID-19 patients, including in the coronary circulation [47–49].
Apart from thrombotic events, systemic inflammation may also contribute to other cardio-
vascular complications.
The systemic inflammation secondary to the infection may result in an increase in
metabolic demand, which may be unmet by cardiomyocytes, potentially precipitating an
ACS [10,50]. Virally-induced systemic inflammation may also precipitate coronary plaque
ruptures and also increases the likelihood of stent thrombosis [50]. A T-helper-1 (Th1)
mediated cytokine storm may potentially contribute to myocardial injury [31,51]. In addi-
tion, inflammatory cytokines can potentially induce cardiac sympathetic hyperactivation
via hypothalamus-mediated and peripheral pathways [52]. Specific cytokines, such as
interleukin (IL)-6, derived from T cells and macrophages, have been implicated in the
inflammatory response and will be further elaborated [53,54].
3.3. The Role of IL-6
IL-6 has multiple potential interactions that have been thought to play an essential role
in cardiovascular complications. IL-6 levels were elevated in COVID-19 patients and could
potentially interact with NETs to drive thrombosis [55]. This pro-inflammatory cytokine
has been thought to induce T lymphocyte activation, resulting in myocardial injury [56].
Together with other pro-inflammatory cytokines, such as IL-1 and tumour necrosis factor-α,
they have been shown to modulate the expression and/or function of K+ and Ca2+ ion
channels in cardiomyocytes, potentially causing arrhythmias [25,52]. IL-6 may potentially
inhibit human Ether-a-go-go-Related Gene (hERG) K+ channels, resulting in QT interval
prolongation [52,57]. It may also inhibit CYP3A4, thus increasing the bioavailability of
certain QT-prolonging drugs [52]. In addition, IL-6 may displace plakoglobin, a desmoso-
mal protein from the cardiomyocyte membrane, which can result in cardiac cell death and
fibrofatty-replacement processes, which can contribute to arrhythmia [56]. IL-6 may also
play a role in acute HF [58].
3.4. Medications and Cardiovascular Complications
Beyond the effects of a direct viral invasion and the body’s inflammatory response,
medications and investigational drug therapies may contribute to cardiovascular com-
plications. An extensive review of this subject is beyond the scope of this review. We
have focused on some cardiovascular complications related to chloroquine and the anti-
virals lopinavir, ritonavir and remdesivir, which have been approved for the treatment of
COVID-19 (Table 1) [59]. Chloroquine and hydroxychloroquine (CQ/HCQ) are thought
to alter endosomal pH and reduce glycosylation of the ACE2 receptor, thus prevent-
ing viral entry [60,61]. However, they can potentially prolong QT intervals by block-
ing the hERG K+ channel, which can result in torsade de pointes or sudden cardiac
death [60]. An acute kidney injury secondary to a COVID-19 infection may accumulate
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chloroquine/hydroxychloroquine, resulting in further QT prolongation [62]. Concomitant
use of azithromycin use with hydroxychloroquine increases the risk of QTc prolongation,
especially in patients with high levels of transaminases, which likely indicate a severe
inflammatory response [57]. Loop diuretics, commonly used in volume management and
ARDS, have also been shown to increase the likelihood of prolonged QTc in patients taking
hydroxychloroquine [63]. Chloroquine and hydroxychloroquine may also cause lysosomal
dysfunction and accumulation of glycogen and phospholipids, the effects of which are
cardiotoxic and can result in HF [64].
Table 1. Summary of proposed COVID-19 therapies and their potential cardiovascular complications [8,57,60–66]. Hydrox-
ychloroquine (HCQ); Chloroquine (CQ); Acute Kidney Injury (AKI); Cytochrome P450 2D6 (CYP2D6); Cytochrome P450
3A4 (CYP3A4).
Summary of Proposed COVID-19 Therapies and Potential Cardiovascular Complications
Proposed Therapy Potential Cardiovascular Effects Possible Mechanisms
HCQ or CQ
QT Prolongation
• Blockage of hERG K+ channels
• Toxic HCQ/CQ accumulation secondary to AKI
Cardiotoxicity
• Lysosomal dysfunction→ glycogen/phospholipid accu-
mulation
HCQ + Azithromycin QTc Prolongation (especially thosewith elevated transaminases)
• Azithromycin prolongs QT interval
• Elevated transaminases indicative of pro-inflammatory cy-
tokines which prolong QT
HCQ + Loop Diuretics QTc Prolongation
• Electrolyte derangement by loop diuretics might be a con-
tributory factor
Lopinavir + Ritonavir
Thrombosis (in clopidogrel users)
• CYP3A4 inhibition thus decreased active metabolites of
clopidogrel
Arrhythmia • CYP2D6 inhibition→ CQ accumulation
Remdesivir Bradycardia • Unclear
Another anti-viral therapy proposed for use in SARS-CoV-2 infections, lopinavir-
ritonavir, inhibits CYP3A4, potentially decreasing serum concentrations of the active
metabolites of P2Y12 inhibitors, such as clopidogrel, which could result in thrombosis [8].
Lopinavir-ritonavir can also inhibit CYP2D6, which potentially increases chloroquine
plasma levels, resulting in malignant arrhythmias [65]. Apart from these investigational
therapies, other factors, ranging from channelopathies to medication compliance, may
also contribute to cardiovascular complications. As for the approved anti-viral agent,
remdesivir, there has been reported episodes of bradycardia related to its use [66].
3.5. Other Contributing Factors
Inherited arrhythmia syndromes may be precipitated during a COVID-19 infection.
Fever is known to trigger arrhythmia in the presence of LQTS 2 mutations (LQTS) or SCN5A
mutations (Brugada syndrome), while diarrhoea can potentially cause hypokalaemia, affect-
ing QTc interval and thus can be detrimental in these inherited arrhythmia syndromes [67].
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Withdrawal of Renin-Angiotensin-Aldosterone system (RAAS) inhibitors due to mis-
informed concerns of increased infection risks can also contribute to decompensation in
HF patients, especially since plasma levels of angiotensin II, aldosterone, cortisol, nore-
pinephrine, left ventricular end-diastolic, and end-systolic volumes return to pre-treatment
values upon cessation of these drugs [68,69]. While the incidence is not yet known, patients
may possibly stop anti-coagulant medications due to misinformation, which can potentially
result in a thrombotic event [70].
Severe illness, hypoxia, mechanical ventilation, central venous catheterisation, de-
hydration, obesity, and immobility may contribute to the observed thromboembolic
events [70,71]. COVID-19, being an acute respiratory infection, may also trigger atrial
fibrillation (AF), which could also be a potential cause of thromboembolic events [72].
While the exact incidence of new-onset AF is unknown, it has been estimated to occur
in 3.6 to 6.7% of COVID-19 patients based on some case reports and clinical studies [73].
Pulmonary hypertension secondary to ARDS and/or PE may lead to HF [25]. Furthermore,
electrolyte derangements and adrenergic stress can lead to electrical instability [25].
A diverse range of proposed pathophysiological mechanisms potentially underlie the
cardiovascular complications associated with an ongoing COVID-19 infection. Understand-
ing these mechanisms may, therefore, aid in devising a targeted management plan that can
potentially reduce the occurrence or improve the outcomes of associated cardiovascular
complications. While these complications were observed to occur during the initial phase
of the infection, emerging evidence suggests that cardiovascular complications may extend
beyond. This will be touched upon in the next section.
4. Long COVID
With the progression of the global COVID-19 pandemic, there is increasing evidence
that some patients are experiencing prolonged symptoms often involving multiple organs
and systems beyond the initial period of the acute COVID-19 infection. There is now
guidance from the National Institute for Health and Care Excellence regarding what has
been termed Long COVID [74]. Long COVID includes ongoing signs and symptoms of
COVID-19 for 4 to 12 weeks after the acute infection, and/or the persistence or development
of signs and symptoms beyond 12 weeks from the onset of a COVID-19 infection [75].
However, it should be noted that it has not been fully defined, as there is still much to
understand about this condition [76]. Signs and symptoms include fatigue, dyspnoea, joint
pain, chest pain, cough, palpitations, anosmia, dysgeusia, alopecia, cognitive blunting, and
psychological distress (Table 2) [77,78]. It is of concern that after 60 days from the onset
of infection, as many as 87.4% of 143 patients in an Italian study were affected by Long
COVID symptoms [77,79].
The use of imaging modalities may help us to understand the cardiovascular in-
volvement in Long COVID. Imaging studies have observed cardiovascular changes that
occur following a COVID-19 infection [80–83]. Myocardial oedema and late gadolinium
enhancement (LGE) have been observed in 58% of 26 Chinese patients presenting with
Long COVID cardiac symptoms [84]. Myocarditis-pattern LGE have been observed up
to a month post-infection in 27% of 148 patients in the UK who have had myocardial
injury; among which, one-third had findings consistent with an active myocarditis [85].
Furthermore, up to 78% of 100 mild COVID-19 cases in Germany—despite having fewer
co-morbidities—had CMR abnormalities of similar extent and severity to that of patients
requiring hospitalization [86]. Thus, while cardiovascular changes have been observed
following a COVID-19 infection, its relationship with Long COVID is still unclear. Fur-
thermore, we are unsure if there are other cardiovascular changes that have been yet to be
detected.
5. Vaccine-Induced Thrombosis
Cardiovascular complications are not yet out of the picture despite the introduction
of vaccines against COVID-19. There have been reports streaming in on the occurrence
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of thromboembolic events following ChAdOx1 nCov-19 (AstraZeneca) vaccination and
potentially the Ad26.COV2.S (Johnson & Johnson) vaccination. While rare, thrombosis was
observed to occur at unusual sites, such as cerebral and splanchnic veins [87–89]. Based on
the observation of thrombocytopenia and raised antibodies to platelet factor 4-polyanion
complexes, it has been suggested to be an immune-mediated reaction [87,88]. This is of
importance, as clinicians must be vigilant for cardiovascular complications not just in the
acute or convalescent phase of a COVID-19 infection but also after a seemingly innocuous
vaccination against the virus.
Table 2. Prevalence of Long COVID Manifestations [7,10,12,16,21,31,77,78,85,90,91]; (-) indicates that
the sign/symptom has not been observed; highlighted in blue denotes the signs/symptoms common
to both acute COVID-19 infection and Long COVID.
Prevalence of Cardiovascular Manifestations
Signs/Symptoms Acute COVID-19 Long COVID
Palpitations/Arrhythmia 16.7% 11.2%




Heart Failure 23.0% -
Prevalence of Other Manifestations











Nasal Congestion 4.8% -
Rhinorrhoea 2.4% -
Alopecia - 28.6%
Cognitive Blunting - 15.0%
Psychological Distress - 22.7%
6. Conclusions
SARS-CoV-2 was first detected in China in 2019 and has spread across the globe with
widespread effects. More than just a respiratory illness, it has shown a preponderance
to those with underlying cardiovascular co-morbidities [31]. In addition, cardiovascular
complications have occurred frequently in association with the disease and even months
after the infection [8,84–86,92]. These cardiovascular complications include myocardial
injury and myocarditis, acute coronary syndromes, heart failure, arrythmias, and throm-
boembolic events. Some of the medications utilised to treat COVID-19 also have potential
cardiac complications [8,57,60–63,65].
In addition, cardiac symptoms, such as palpitations, chest pain, and dyspnoea and
CMR changes, have been observed in patients weeks to months after the initial infection
in what has been termed Long COVID [77,79,84–86]. Autonomic dysfunction could be
a contributor to the underlying pathophysiological mechanism of these symptoms [92].
Chronic myocarditis leading to myocardial fibrosis and the subsequent development
of arrhythmias may potentially account for some of these symptoms as well [56]. The
significance of the observed cardiovascular changes is still not well understood; nor do we
know if there will be more to be detected [76].
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The exact pathophysiological mechanisms underlying the disease and its cardiovas-
cular sequelae are still largely speculative. Further research must be performed to better
understand COVID-19 and its long-term complications.
Author Contributions: Writing—original draft preparation, C.C.E.L., C.C.L.; writing—review and
editing, C.C.E.L., K.A., D.C., I.R.M., J.G., E.M.L., C.C.L.; supervision, C.C.L. All authors have read
and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Guzik, T.J.; Mohiddin, S.A.; DiMarco, A.; Patel, V.; Savvatis, K.; Marelli-Berg, F.M.; Madhur, M.S.; Tomaszewski, M.; Maffia, P.;
D’Acquisto, F.; et al. COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options.
Cardiovasc. Res. 2020, 116, 1666–1687. [CrossRef]
2. World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation Report—51. 2020. Available online: https://www.
who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10 (accessed
on 28 January 2021).
3. World Health Organization. Weekly Epidemiological Update—29 December 2020. 2020. Available online: https://www.who.int/
publications/m/item/weekly-epidemiological-update---29-december-2020 (accessed on 28 January 2021).
4. Astuti, I. Ysrafil Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host
response. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 407–412. [CrossRef]
5. Zhang, Y.-Z.; Holmes, E.C. A Genomic Perspective on the Origin and Emergence of SARS-CoV-2. Cell 2020, 181, 223–227.
[CrossRef]
6. Epidemiology Working Group for NCIP Epidemic Response; Chinese Center for Disease Control and Prevention. The epidemio-
logical characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi
2020, 41, 145–151.
7. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; et al. Clinical Characteristics
of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020, 323, 1061–1069.
[CrossRef]
8. Driggin, E.; Madhavan, M.V.; Bikdeli, B.; Chuich, T.; Laracy, J.; Biondi-Zoccai, G.; Brown, T.S.; Der-Nigoghossian, C.; Zidar, D.A.;
Haythe, J.; et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19
Pandemic. J. Am. Coll. Cardiol. 2020, 75, 2352–2371. [CrossRef]
9. Cui, S.; Chen, S.; Li, X.; Liu, S.; Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus
pneumonia. J. Thromb. Haemost. 2020, 18, 1421–1424. [CrossRef] [PubMed]
10. Lala, A.; Johnson, K.; Januzzi, J.L.; Russak, A.J.; Paranjpe, I.; Richter, F.; Zhao, S.; Somani, S.; Van Vleck, T.; Vaid, A.; et al.
Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J. Am. Coll. Cardiol. 2020, 76,
533–546. [CrossRef] [PubMed]
11. Cammann, V.L.; Szawan, K.A.; D’Ascenzo, F.; Gili, S.; Dreiding, S.; Würdinger, M.; Manka, R.; Stähli, B.E.; Holy, E.W.; Siegrist, P.;
et al. Outcomes of acute coronary syndromes in coronavirus disease 2019. Clin. Res. Cardiol. Off. J. Ger. Card. Soc. 2020, 109,
1601–1604. [CrossRef] [PubMed]
12. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors
for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062.
[CrossRef]
13. Lax, S.F.; Skok, K.; Zechner, P.; Kessler, H.H.; Kaufmann, N.; Koelblinger, C.; Vander, K.; Bargfrieder, U.; Trauner, M. Pulmonary
Arterial Thrombosis in COVID-19 With Fatal Outcome: Results from a Prospective, Single-Center, Clinicopathologic Case Series.
Ann. Intern. Med. 2020, 173, 350–361. [CrossRef] [PubMed]
14. Campbell, C.; Kahwash, R. Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis?
Circulation 2020, 141, 1739–1741. [CrossRef] [PubMed]
15. Helms, J.; Tacquard, C.; Severac, F.; Leonard-Lorant, I.; Ohana, M.; Delabranche, X.; Merdji, H.; Clere-Jehl, R.; Schenck, M.;
Gandet, F.F.; et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study.
Intensive Care Med. 2020, 46, 1089–1098. [CrossRef] [PubMed]
16. Middeldorp, S.; Coppens, M.; Van Haaps, T.F.; Foppen, M.; Vlaar, A.P.; Müller, M.C.A.; Bouman, C.C.S.; Beenen, L.F.M.; Kootte,
R.S.; Heijmans, J.; et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J. Thromb. Haemost. 2020,
18, 1995–2002. [CrossRef]
17. Wichmann, D. Autopsy Findings and Venous Thromboembolism in Patients with COVID-19. Ann. Intern. Med. 2020, 173, 1030.
[CrossRef]
Diseases 2021, 9, 47 10 of 13
18. Malas, M.B.; Naazie, I.N.; Elsayed, N.; Mathlouthi, A.; Marmor, R.; Clary, B. Thromboembolism risk of COVID-19 is high
and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine 2020, 29–30, 100639.
[CrossRef]
19. Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Chaitman, B.R.; Bax, J.J.; Morrow, D.A.; White, H.D.; ESC Scientific Document Group. Fourth
universal definition of myocardial infarction. Eur. Heart J. 2018, 40, 237–269. [CrossRef]
20. Liu, P.P.; Blet, A.; Smyth, D.; Li, H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation
2020, 142, 68–78. [CrossRef]
21. Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q.; et al. Association of Cardiac Injury with
Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020, 5, 802. [CrossRef]
22. Guo, T.; Fan, Y.; Chen, M.; Wu, X.; Zhang, L.; He, T.; Wang, H.; Wan, J.; Wang, X.; Lu, Z. Cardiovascular Implications of Fatal
Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020, 5, 811–818. [CrossRef]
23. Bangalore, S.; Sharma, A.; Slotwiner, A.; Yatskar, L.; Harari, R.; Shah, B.; Ibrahim, H.; Friedman, G.H.; Thompson, C.; Alviar, C.L.;
et al. ST-Segment Elevation in Patients with Covid-19—A Case Series. N. Engl. J. Med. 2020, 382, 2478–2480. [CrossRef]
24. Stefanini, G.G.; Montorfano, M.; Trabattoni, D.; Andreini, D.; Ferrante, G.; Ancona, M.; Metra, M.; Curello, S.; Maffeo, D.; Pero, G.;
et al. ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes. Circulation 2020, 141,
2113–2116. [CrossRef] [PubMed]
25. Boukhris, M.; Hillani, A.; Moroni, F.; Annabi, M.S.; Addad, F.; Ribeiro, M.H.; Mansour, S.; Zhao, X.; Ybarra, L.F.; Abbate, A.; et al.
Cardiovascular Implications of the COVID-19 Pandemic: A Global Perspective. Can. J. Cardiol. 2020, 36, 1068–1080. [CrossRef]
[PubMed]
26. Turagam, M.K.; Musikantow, D.; Goldman, M.E.; Bassily-Marcus, A.; Chu, E.; Shivamurthy, P.; Lampert, J.; Kawamura, I.;
Bokhari, M.; Whang, W.; et al. Malignant Arrhythmias in Patients with COVID-19: Incidence, Mechanisms, and Outcomes. Circ.
Arrhythmia Electrophysiol. 2020, 13, e008920. [CrossRef] [PubMed]
27. Liao, S.-C.; Shao, S.-C.; Cheng, C.-W.; Chen, Y.-C.; Hung, M.-J. Incidence rate and clinical impacts of arrhythmia following
COVID-19: A systematic review and meta-analysis of 17,435 patients. Crit. Care 2020, 24, 1–7. [CrossRef]
28. Chen, T.; Wu, D.; Chen, H.; Yan, W.; Yang, D.; Chen, G.; Ma, K.; Xu, D.; Yu, H.; Wang, H.; et al. Clinical characteristics of 113
deceased patients with coronavirus disease 2019: Retrospective study. BMJ 2020, 368, m1091. [CrossRef] [PubMed]
29. Zhang, Y.; Coats, A.J.S.; Zheng, Z.; Adamo, M.; Ambrosio, G.; Anker, S.D.; Butler, J.; Xu, D.; Mao, J.; Khan, M.S.; et al. Management
of heart failure patients withCOVID-19: A joint position paper of the Chinese Heart Failure Association & National Heart Failure
Committee and the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2020, 22, 941–956.
[CrossRef]
30. Rey, J.R.; Caro-Codón, J.; Rosillo, S.O.; Iniesta, Á.M.; Castrejón-Castrejón, S.; Marco-Clement, I.; Martín-Polo, L.; Merino-Argos,
C.; Rodríguez-Sotelo, L.; García-Veas, J.M.; et al. Heart failure in COVID-19 patients: Prevalence, incidence and prognostic
implications. Eur. J. Heart Failure 2020. [CrossRef]
31. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [CrossRef]
32. Sattar, N.; Ho, F.K.; Gill, J.M.; Ghouri, N.; Gray, S.; Celis-Morales, C.A.; Katikireddi, S.V.; Berry, C.; Pell, J.P.; McMurray, J.J.; et al.
BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank.
Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 1149–1151. [CrossRef]
33. Docherty, A.B.; Harrison, E.M.; Green, C.A.; Hardwick, H.E.; Pius, R.; Norman, L.; Holden, K.A.; Read, J.M.; Dondelinger, F.;
Carson, G.; et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation
Protocol: Prospective observational cohort study. BMJ 2020, 369, m1985. [CrossRef]
34. Vaduganathan, M.; Vardeny, O.; Michel, T.; McMurray, J.J.V.; Pfeffer, M.A.; Solomon, S.D. Renin–Angiotensin–Aldosterone System
Inhibitors in Patients with Covid-19. N. Engl. J. Med. 2020, 382, 1653–1659. [CrossRef]
35. Grimes, J.M.; Grimes, K.V. p38 MAPK Inhibition: A Promising Therapeutic Approach for COVID-19. J. Mol. Cell. Cardiol. 2020,
144, 63–65. [CrossRef] [PubMed]
36. Jia, H.P.; Look, D.C.; Shi, L.; Hickey, M.; Pewe, L.; Netland, J.; Farzan, M.; Wohlford-Lenane, C.; Perlman, S.; McCray, P.B. ACE2
Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway
Epithelia. J. Virol. 2005, 79, 14614–14621. [CrossRef]
37. Walls, A.C.; Park, Y.J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Veesler, D. Structure, Function, and Antigenicity of the SARS-CoV-2
Spike Glycoprotein: Cell. Cell 2020, 181, 281–292. [CrossRef] [PubMed]
38. Tavazzi, G.; Pellegrini, C.; Maurelli, M.; Belliato, M.; Sciutti, F.; Bottazzi, A.; Sepe, P.A.; Resasco, T.; Camporotondo, R.; Bruno, R.;
et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur. J. Heart Fail. 2020, 22, 911–915. [CrossRef]
[PubMed]
39. Chen, L.; Li, X.; Chen, M.; Feng, Y.; Xiong, C. The ACE2 Expression in Human Heart Indicates New Potential Mechanism of
Heart Injury Among Patients Infected with SARS-CoV-2. Cardiovasc. Res. 2020, 116, 1097–1100. [CrossRef]
40. Leisman, D.; Deutschman, C.S.; Legrand, M. Facing COVID-19 in the ICU: Vascular dysfunction, thrombosis, and dysregulated
inflammation. Intensiv. Care Med. 2020, 46, 1105–1108. [CrossRef] [PubMed]
41. Jecko, T.; Alok, S. SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or
Pulmonary Embolism? Semin. Thromb. Hemost. 2020, 46, 777–780.
Diseases 2021, 9, 47 11 of 13
42. Violi, F.; Pastori, D.; Pignatelli, P.; Cangemi, R. SARS-CoV-2 and Myocardial Injury: A Role for Nox2? Intern. Emerg. Med. 2020,
15, 755–758. [CrossRef]
43. Nicolau, L.; Magalhães, P.J.; Vale, M.L. What would Sérgio Ferreira say to your physician in this war against COVID-19: How
about kallikrein/kinin system? Med. Hypotheses 2020, 143, 109886. [CrossRef]
44. Giannis, D.; Ziogas, I.A.; Gianni, P. Coagulation Disorders in Coronavirus Infected Patients: COVID-19, SARS-CoV-1, MERS-CoV
and Lessons from the Past. J. Clin. Virol. 2020, 127, 104362. [CrossRef] [PubMed]
45. Libby, P.; Lüscher, T. COVID-19 is, in the end, an endothelial disease. Eur. Heart J. 2020, 41, 3038–3044. [CrossRef]
46. Sardu, C.; Gambardella, J.; Morelli, M.B.; Wang, X.; Marfella, R.; Santulli, G. Hypertension, Thrombosis, Kidney Failure, and
Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J. Clin. Med. 2020, 9,
1417. [CrossRef]
47. Panigada, M.; Bottino, N.; Tagliabue, P.; Grasselli, G.; Novembrino, C.; Chantarangkul, V.; Pesenti, A.; Peyvandi, F.; Tripodi, A.
Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters
of hemostasis. J. Thromb. Haemost. 2020, 18, 1738–1742. [CrossRef] [PubMed]
48. Zuo, Y.; Zuo, M.; Yalavarthi, S.; Gockman, K.; Madison, J.A.; Shi, H.; Woodard, W.; Lezak, S.P.; Lugogo, N.L.; Knight, J.S.; et al.
Neutrophil extracellular traps and thrombosis in COVID-19. J. Thromb. Thrombolysis 2020, 51, 446–453. [CrossRef]
49. Blasco, A.; Coronado, M.-J.; Hernández-Terciado, F.; Martín, P.; Royuela, A.; Ramil, E.; García, D.; Goicolea, J.; Del Trigo, M.;
Ortega, J.; et al. Assessment of Neutrophil Extracellular Traps in Coronary Thrombus of a Case Series of Patients with COVID-19
and Myocardial Infarction. JAMA Cardiol. 2021, 6, 469. [CrossRef]
50. Xiong, T.-Y.; Redwood, S.; Prendergast, B.; Chen, M. Coronaviruses and the cardiovascular system: Acute and long-term
implications. Eur. Heart J. 2020, 41, 1798–1800. [CrossRef] [PubMed]
51. Zheng, Y.Y.; Ma, Y.T.; Zhang, J.Y.; Xie, X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020, 17, 259–260. [CrossRef]
52. Lazzerini, P.E.; Boutjdir, M.; Capecchi, P. COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap! Circulation 2020, 142, 7–9.
[CrossRef]
53. McElvaney, O.J.; Curley, G.F.; Rose-John, S.; McElvaney, N.G. Interleukin-6: Obstacles to targeting a complex cytokine in critical
illness. Lancet Respir. Med. 2021, 9, 643–654. [CrossRef]
54. Rubin, E.J.; Longo, D.L.; Baden, L.R. Interleukin-6 Receptor Inhibition in Covid-19—Cooling the Inflammatory Soup. N. Engl. J.
Med. 2021, 384, 1564–1565. [CrossRef]
55. Zuo, Y.; Yalavarthi, S.; Shi, H.; Gockman, K.; Zuo, M.; Madison, J.A.; Blair, C.; Weber, A.; Barnes, B.J.; Egeblad, M.; et al. Neutrophil
Extracellular Traps (NETs) as Markers of Disease Severity in COVID-19 [Preprint]. medRxiv 2020. [CrossRef]
56. Siripanthong, B.; Nazarian, S.; Muser, D.; Deo, R.; Santangeli, P.; Khanji, M.Y.; Cooper, L.T.; Chahal, C.A.A. Recognizing COVID-
19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm
2020, 17, 1463–1471. [CrossRef] [PubMed]
57. Cipriani, A.; Zorzi, A.; Ceccato, D.; Capone, F.; Parolin, M.; Donato, F.; Fioretto, P.; Pesavento, R.; Previato, L.; Maffei, P.; et al.
Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.
Int. J. Cardiol. 2020, 316, 280–284. [CrossRef]
58. Belhadjer, Z.; Méot, M.; Bajolle, F.; Khraiche, D.; Legendre, A.; Abakka, S.; Auriau, J.; Grimaud, M.; Oualha, M.; Beghetti, M.;
et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children (MIS-C) in the Context of Global SARS-CoV-2
Pandemic. Circulation 2020, 142, 429–436. [CrossRef]
59. FDA—U.S. Food & Drug Administration. FDA Approves First Treatment for COVID-19. 2020. Available online: https:
//www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 (accessed on 11 May 2021).
60. Giudicessi, J.R.; Noseworthy, P.A.; Friedman, P.A.; Ackerman, M.J. Urgent Guidance for Navigating and Circumventing the
QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clin.
Proc. 2020, 95, 1213–1221. [CrossRef] [PubMed]
61. Younis, N.K.; Zareef, R.O.; Al Hassan, S.N.; Bitar, F.; Eid, A.H.; Arabi, M. Hydroxychloroquine in COVID-19 Patients: Pros and
Cons. Front. Pharmacol. 2020, 11, 597985. [CrossRef]
62. Jankelson, L.; Karam, G.; Becker, M.L.; Chinitz, L.A.; Tsai, M.-C. QT prolongation, torsades de pointes, and sudden death with
short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart Rhythm 2020, 17, 1472–1479.
[CrossRef] [PubMed]
63. Mercuro, N.J.; Yen, C.F.; Shim, D.J.; Maher, T.R.; McCoy, C.M.; Zimetbaum, P.J.; Gold, H.S. Risk of QT Interval Prolongation
Associated with Use of Hydroxychloroquine with or Without Concomitant Azithromycin Among Hospitalized Patients Testing
Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020, 5, 1036–1041. [CrossRef] [PubMed]
64. Aggarwal, G.; Henry, B.M.; Aggarwal, S.; Bangalore, S. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus
Disease 2019. Am. J. Cardiol. 2020, 128, 147–150. [CrossRef]
65. Pastick, K.A.; Okafor, E.C.; Wang, F.; Lofgren, S.M.; Skipper, C.P.; Nicol, M.R.; Pullen, M.F.; Rajasingham, R.; McDonald, E.G.; Lee,
T.C.; et al. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infect. Dis.
2020, 7, 130. [CrossRef]
66. Pallotto, C.; Suardi, L.R.; Gabbuti, A.; Esperti, S.; Mecocci, L.; Blanc, P. Potential remdesivir-related transient bradycardia in
patients with coronavirus disease 2019 (COVID-19). J. Med Virol. 2021, 93, 2631–2634. [CrossRef] [PubMed]
Diseases 2021, 9, 47 12 of 13
67. Wu, C.-I.; Postema, P.G.; Arbelo, E.; Behr, E.R.; Bezzina, C.R.; Napolitano, C.; Robyns, T.; Probst, V.; Schulze-Bahr, E.; Remme, C.A.;
et al. SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Heart Rhythm 2020, 17, 1456–1462. [CrossRef] [PubMed]
68. Buckley, L.F.; Cheng, J.W.M.; Desai, A. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin
Converting Enzyme 2. J. Cardiovasc. Pharmacol. 2020, 75, 526–529. [CrossRef] [PubMed]
69. Hippisley-Cox, J.; Young, D.; Coupland, C.; Channon, K.M.; Tan, P.S.; Harrison, D.A.; Rowan, K.; Aveyard, P.; Pavord, I.D.;
Watkinson, P.J. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: Cohort study including
8.3 million people. Heart 2020, 106, 1503–1511. [CrossRef]
70. Bikdeli, B.; Madhavan, M.V.; Jimenez, D.; Chuich, T.; Dreyfus, I.; Driggin, E.; Der Nigoghossian, C.; Ageno, W.; Madjid, M.; Guo,
Y.; et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and
Follow-Up: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020, 75, 2950–2973. [CrossRef]
71. Zhai, Z.; Li, C.; Chen, Y.; Gerotziafas, G.; Zhang, Z.; Wan, J.; Liu, P.; Elalamy, I.; Wang, C. Prevention and Treatment of Venous
Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. Thromb.
Haemost. 2020, 120, 937–948. [CrossRef]
72. Watson, R.A.; Johnson, D.M.; Dharia, R.N.; Merli, G.J.; Doherty, J.U. Anti-coagulant and anti-platelet therapy in the COVID-19
patient: A best practices quality initiative across a large health system. Hosp. Pract. 2020, 48, 169–179. [CrossRef]
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